{"url_path":"/sec/kapa/8-k/2026-05-18/item-8-01","section_key":"item-8-01","section_title":"Item 8.01 Other Events.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-18","source_url":"https://www.sec.gov/Archives/edgar/data/1962011/0001493152-26-024082-index.html","accession_number":"0001493152-26-024082","cik":"0001962011","ticker":"KAPA","issuer_name":"Kairos Pharma, LTD.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1962011/0001493152-26-024082-index.html","primary_entity_key":"0001962011","primary_entity_name":"Kairos Pharma, LTD."},"word_count":182,"has_tables":true,"body_markdown":"**Item\n8.01. Other Events.**\n\n \n\nOn\nMay 18, 2026, Kairos Pharma, Ltd., a Delaware corporation (the “Company”), issued a new investor presentation, which will\nbe published on the Company’s website, www.kairospharma.com, and presented today\nat the 2026 LD Micro Invitational XVI (the “LD Micro Invitational”), set to take place in Los Angeles, CA May 18-19, 2026.\nAs part of its participation in the LD Micro Invitational, the Company’s Chief Executive Officer, John Yu, will present the investor\npresentation to provide an update on the Company’s clinical program and partnering activities.\n\n \n\nA\ncopy of the investor presentation is being furnished as Exhibit 99.1 to this Form 8-K. The information included in this Item 8.01, including\nExhibit 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act\nof 1934, as amended (the “Exchange Act”), or otherwise subject to liabilities under that section, and shall not be deemed\nto be incorporated by reference into the filings of the Company under the Securities Act or the Exchange Act, regardless of any general\nincorporation language in such filings."}